{"nctId":"NCT02939287","briefTitle":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","startDateStruct":{"date":"2017-09-23","type":"ACTUAL"},"conditions":["Nausea","Vomiting"],"count":52,"armGroups":[{"label":"Aprepitant","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1"]},{"label":"Olanzapine","type":"EXPERIMENTAL","interventionNames":["Drug: Olanzapine10 mg orally daily on Days -1,0,+1 and +2"]},{"label":"Aprepitant plus olanzapine","type":"EXPERIMENTAL","interventionNames":["Drug: Aprepitant plus Olanzapine"]}],"interventions":[{"name":"o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1","otherNames":["Emend"]},{"name":"Olanzapine10 mg orally daily on Days -1,0,+1 and +2","otherNames":["Zyprexa"]},{"name":"Aprepitant plus Olanzapine","otherNames":["Emend","Zyprexa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Autologous transplant containing high dose melphalan as part of the conditioning regimen (single or 2 day melphalan; BEAM \\[carmustine, etoposide, cytarabine, melphalan\\])\n* able to tolerate oral medications\n\nExclusion Criteria:\n\n* Nausea/vomiting within 12 hours before planned high dose conditioning chemotherapy\n* Any anti-emetic treatment within 24 hours before planned high dose conditioning chemotherapy\n* Pregnancy\n* Baseline corrected QT interval (QTc) \\> 500 ms\n* History of seizures\n* History of central nervous system (CNS) disease\n* Human immunodeficiency virus (HIV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Response (CR)","description":"no emesis and no rescue anti-emetic therapy","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Acute Complete Response","description":"no emesis or rescue therapy; Acute complete response defined as no emesis or rescue therapy required from time point of 0 to 24 hours following melphalan therapy administration","classes":[]},{"type":"SECONDARY","title":"Delayed Complete Response","description":"no emesis or rescue therapy administered; Delayed complete response defined as no emesis or rescue therapy required from time point of 25 hours to 120 hours following melphalan therapy administration","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":14},"commonTop":[]}}}